FR2459246A1 - Complexes cis-lactate de platine (ii) amine, medicaments et compositions pharmaceutiques les contenant - Google Patents
Complexes cis-lactate de platine (ii) amine, medicaments et compositions pharmaceutiques les contenant Download PDFInfo
- Publication number
- FR2459246A1 FR2459246A1 FR8013507A FR8013507A FR2459246A1 FR 2459246 A1 FR2459246 A1 FR 2459246A1 FR 8013507 A FR8013507 A FR 8013507A FR 8013507 A FR8013507 A FR 8013507A FR 2459246 A1 FR2459246 A1 FR 2459246A1
- Authority
- FR
- France
- Prior art keywords
- cis
- lactate
- platinum
- complex according
- complexes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- -1 PLATINUM (II) AMINE Chemical class 0.000 title description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 21
- 150000003973 alkyl amines Chemical class 0.000 claims abstract description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 46
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 32
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- CPBWHVPEXLELDF-UHFFFAOYSA-L 2-hydroxypropanoate;platinum(2+) Chemical compound [Pt+2].CC(O)C([O-])=O.CC(O)C([O-])=O CPBWHVPEXLELDF-UHFFFAOYSA-L 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 229940095054 ammoniac Drugs 0.000 abstract 1
- 229940001447 lactate Drugs 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 13
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 229910021607 Silver chloride Inorganic materials 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 5
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 150000003893 lactate salts Chemical class 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000816 toxic dose Toxicity 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DYQHASUHNNRLRA-UHFFFAOYSA-L C(C(O)C)(=O)[O-].[Pt+2].C(CN)N.C(C(O)C)(=O)[O-] Chemical compound C(C(O)C)(=O)[O-].[Pt+2].C(CN)N.C(C(O)C)(=O)[O-] DYQHASUHNNRLRA-UHFFFAOYSA-L 0.000 description 1
- 101100135641 Caenorhabditis elegans par-3 gene Proteins 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UIESMAIMBNSQQX-UHFFFAOYSA-N cyclohexane platinum Chemical compound [Pt].C1CCCCC1 UIESMAIMBNSQQX-UHFFFAOYSA-N 0.000 description 1
- KMEQMZMYKYCLMS-UHFFFAOYSA-N cyclohexane platinum(2+) Chemical compound [Pt+2].C1CCCCC1 KMEQMZMYKYCLMS-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- POQBJIOLWPDPJE-UHFFFAOYSA-N cyclohexane-1,2-diamine;platinum Chemical compound [Pt].NC1CCCCC1N POQBJIOLWPDPJE-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XXBOARRUKJZXRP-UHFFFAOYSA-N ethane-1,2-diamine;platinum(2+) Chemical compound [Pt+2].NCCN XXBOARRUKJZXRP-UHFFFAOYSA-N 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/050,235 US4271085A (en) | 1979-06-20 | 1979-06-20 | Cis-platinum (II) amine lactate complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2459246A1 true FR2459246A1 (fr) | 1981-01-09 |
| FR2459246B1 FR2459246B1 (forum.php) | 1984-11-23 |
Family
ID=21964121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8013507A Granted FR2459246A1 (fr) | 1979-06-20 | 1980-06-18 | Complexes cis-lactate de platine (ii) amine, medicaments et compositions pharmaceutiques les contenant |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4271085A (forum.php) |
| JP (1) | JPS5645495A (forum.php) |
| AU (1) | AU537574B2 (forum.php) |
| CA (1) | CA1134378A (forum.php) |
| DE (1) | DE3023111A1 (forum.php) |
| FR (1) | FR2459246A1 (forum.php) |
| GB (1) | GB2053212B (forum.php) |
| IT (1) | IT1149202B (forum.php) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5716895A (en) * | 1980-07-05 | 1982-01-28 | Otsuka Chem Co Ltd | Platinum 2 complex and antitumor agent containing the same as active principle |
| JPS57123198A (en) * | 1981-01-23 | 1982-07-31 | Shionogi & Co Ltd | Novel platinum complex |
| JPS59112995A (ja) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | 新規グリコ−ル酸白金錯体 |
| US4598091A (en) * | 1983-02-18 | 1986-07-01 | Degussa Aktiengesellschaft | (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds |
| US4720504A (en) * | 1983-05-10 | 1988-01-19 | Andrulis Research Corporation | Use of bis-platinum complexes as antitumor agents |
| US4565884A (en) * | 1983-05-10 | 1986-01-21 | Andrulis Research Corporation | Bis-platinum complexes as antitumor agents |
| WO1984004524A1 (en) * | 1983-05-10 | 1984-11-22 | Andrulis Res Corp | Bis-platinum complexes as antitumor agents |
| JPS59222498A (ja) * | 1983-06-01 | 1984-12-14 | Shionogi & Co Ltd | 新規グリコ−ル酸系白金錯体および抗悪性腫瘍剤 |
| US4562275A (en) * | 1984-03-23 | 1985-12-31 | Bristol-Myers Co. | Antitumor platinum complexes |
| JPS617283A (ja) * | 1984-06-20 | 1986-01-13 | Shionogi & Co Ltd | 新規白金錯体および抗悪性腫瘍剤 |
| US5041581A (en) * | 1985-10-18 | 1991-08-20 | The University Of Texas System Board Of Regents | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5384127A (en) * | 1985-10-18 | 1995-01-24 | Board Of Regents, The University Of Texas System | Stable liposomal formulations of lipophilic platinum compounds |
| US5117022A (en) * | 1985-10-18 | 1992-05-26 | The Board Of Regents, The University Of Texas System | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5041578A (en) * | 1988-11-22 | 1991-08-20 | Board Of Regents, The University Of Texas System | Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents |
| US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5434256A (en) * | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5130450A (en) * | 1990-04-25 | 1992-07-14 | Nippon Kayaku Kabushiki Kaisha | Platinum complexes |
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| US7138520B2 (en) * | 2003-01-13 | 2006-11-21 | Massachusetts Institute Of Technology | Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2329485A1 (de) * | 1972-06-08 | 1973-12-20 | Research Corp | Platinkoordinationsverbindungen |
| EP0001126A1 (en) * | 1977-09-12 | 1979-03-21 | Yoshinori Kidani | Cis-platinum (II) complexes of 1,2-diamino-cyclohexane and pharmaceutical composition containing them |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS535369A (en) * | 1976-07-02 | 1978-01-18 | Fuji Iron Works | Goods selecting apparatus in wind changing machine |
| US4115418A (en) * | 1976-09-02 | 1978-09-19 | Government Of The United States Of America | 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity |
-
1979
- 1979-06-20 US US06/050,235 patent/US4271085A/en not_active Expired - Lifetime
-
1980
- 1980-06-12 CA CA000353897A patent/CA1134378A/en not_active Expired
- 1980-06-14 JP JP7963080A patent/JPS5645495A/ja active Granted
- 1980-06-18 IT IT49001/80A patent/IT1149202B/it active
- 1980-06-18 GB GB8019975A patent/GB2053212B/en not_active Expired
- 1980-06-18 AU AU59368/80A patent/AU537574B2/en not_active Ceased
- 1980-06-18 FR FR8013507A patent/FR2459246A1/fr active Granted
- 1980-06-20 DE DE19803023111 patent/DE3023111A1/de active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2329485A1 (de) * | 1972-06-08 | 1973-12-20 | Research Corp | Platinkoordinationsverbindungen |
| EP0001126A1 (en) * | 1977-09-12 | 1979-03-21 | Yoshinori Kidani | Cis-platinum (II) complexes of 1,2-diamino-cyclohexane and pharmaceutical composition containing them |
Non-Patent Citations (1)
| Title |
|---|
| Chemical Abstracts vol. 19, no. 19, 7 mai 1979, Columbus, Ohio, USA S. YOLLES et al. "Timed-released depot for anticancer agents. II.", page 299, colonne 2, abstract no. 157040u & Acta Pharm. Suec., vol. 15, no. 5, 1978, pages 3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2459246B1 (forum.php) | 1984-11-23 |
| US4271085A (en) | 1981-06-02 |
| GB2053212A (en) | 1981-02-04 |
| IT8049001A0 (it) | 1980-06-18 |
| GB2053212B (en) | 1983-06-22 |
| IT1149202B (it) | 1986-12-03 |
| DE3023111A1 (de) | 1981-01-08 |
| DE3023111C2 (forum.php) | 1988-09-22 |
| AU537574B2 (en) | 1984-07-05 |
| CA1134378A (en) | 1982-10-26 |
| JPS5645495A (en) | 1981-04-25 |
| AU5936880A (en) | 1981-01-08 |
| JPH036156B2 (forum.php) | 1991-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2459246A1 (fr) | Complexes cis-lactate de platine (ii) amine, medicaments et compositions pharmaceutiques les contenant | |
| EP0219936B1 (en) | Novel platinum complexes | |
| EP0039272B1 (fr) | Composé complexe isocitraté du platine, son procédé de préparation et son application thérapeutique | |
| HU183014B (en) | Process for preparing anticanceric pharmaceutical compositions containing platinum-diamine complexes as active substances as well as the platinum-diamine complexes | |
| JP3697210B2 (ja) | 二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法 | |
| CN101289468A (zh) | 一种新型的奥沙利铂衍生物 | |
| FR2534907A1 (fr) | Complexes diamine-platine, un procede pour leur preparation, un procede pour la preparation d'une composition medicinale utilisant un tel complexe diamine platine pour le traitement du cancer ainsi que la composition ainsi formee | |
| JPS63203692A (ja) | 新規白金錯体 | |
| EP0115929A1 (en) | Novel organic platinum complex and process for the preparation thereof | |
| KR100314720B1 (ko) | 포스파젠 삼합체에 도입된 백금 착물, 그의 제조방법 및 그를 유효성분으로 하는 항암제 | |
| US5028727A (en) | Platinum-(IV)-diamine complex | |
| EP0897389B1 (fr) | Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant | |
| FR2459247A1 (fr) | Complexe de cis-ascorbate de platine (ii) amine | |
| EA017521B1 (ru) | Комплексное соединение платины и его применение | |
| US5037812A (en) | Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes | |
| CA1249818A (fr) | Derives de l'oxaazaphosphorine et leur procede de preparation | |
| EP0304566A2 (en) | Water soluble platinum complexes of novel malonate derivatives | |
| EP0482993A1 (fr) | Dérivés N,O spirocycliques de cyclotriphosphazènes, leur préparation et leur application en thérapeutique | |
| CN101914117A (zh) | 含有二氯乙酰氧基的铂(ii)类抗癌配合物 | |
| EP0290169A2 (en) | Diamineplatinum complexes with phosphonocarboxylate and substituted phosphonocarboxylate ligands as antitumor agents | |
| KR940010296B1 (ko) | 신규한 플라티늄(ⅱ) 착화합물과 그의 제조방법 | |
| KR910009822B1 (ko) | 백금 착화합물의 제조방법 | |
| KR940010298B1 (ko) | 신규한 플라티늄(ii) 착화합물과 그의 제조방법 | |
| KR940010297B1 (ko) | 신규한 플라티늄(ii) 착화합물과 그의 제조방법 | |
| JPS6125707B2 (forum.php) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |